drugset / Trial / NCT05619627

Oral Dexmedetomidine in Pediatric MRI

NCT05619627

Phase 1 Not yet recruiting 18 enrolled Children's Mercy Hospital Kansas City
Non-randomizedSequentialOpen-labelSupportive care

Summary

The objective of this preliminary study is to assess the utility of oral dexmedetomidine as the sole sedative agent in pediatric population undergoing MRI.

Timeline

Start
2026-08-01
Primary completion
2027-08
Completion
2027-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 4 ug/kg Oral
Subject Dexmedetomidine Other / unclassified 6 ug/kg Oral
Subject Dexmedetomidine Other / unclassified 8 ug/kg Oral
Subject Dexmedetomidine Other / unclassified 10 ug/kg Oral
Subject Dexmedetomidine Other / unclassified 12 ug/kg Oral

Indications

No indication recorded.